EndoPredict is a second-generation breast cancer recurrence test. Studies have shown EndoPredict to be far superior to the first generation test Oncotype DX. Our earlier blog shares the journey of EndoPredict in India. But how does EndoPredict calculate the breast cancer recurrence score? What is the algorithm of EndoPredict?
The power and accuracy of EndoPredict is the algorithm which takes into account many data points to predict the patient’s likelihood to respond to chemotherapy.
EndoPredict first incorporates a score from the 12 genes tested:
- 8 target genes
- 3 normalization genes
- 1 control gene
Mathematically these 12 genes make up the EP score. The EP score alone is shown to be superior to Oncotype DX.
However, EndoPredict goes even a step further by adding in two more factors:
Tumor Nodal Status
This leads to the magic of powerful accuracy as all these components are analysed together:
Together with the EP score these clinical factors incorporate to get the EPclin score. The combination of the genetic signature of the 12 genes along with the clinical factors is shown to have the strongest prognostic value. The powerful EndoPredict algorithm enables binary classification of Low and High risk resulting a strong clinical answer in 100% of patients.